ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.
Appointment of Lesley Russell to Board of Directors
On November 18, 2016, the Board of Directors of Enanta Pharmaceuticals, Inc. appointed Lesley Russell, MBChB, MRCP to serve as an independent director of the Company in the class of directors whose terms expire at Enanta’s 2019 Annual Meeting of Stockholders. The Board of Directors also appointed Dr. Russell as a member of the Audit and Nominating and Corporate Governance Committees of the Board of Directors, effective as of January 1, 2017.
Dr. Russell will receive the standard compensation for non-employee directors of Enanta, including retainer fees for Board and committee service and stock options, and will have the benefit of the Company’s standard form of indemnification agreement.
Pending Retirement of Ernst-Günter Afting from the Board of Directors
Dr. Ernst-Günter Afting has advised the Board that he will retire as an independent director of Enanta, effective as of the 2017 annual meeting of stockholders. Dr. Afting’s retirement is not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices.
In addition to his service on Enanta’s Board of Directors, Dr. Afting served as a member of the Board’s Audit Committee and its Nominating and Corporate Governance Committee.
About ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA)
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program, the Company is developing agonists of the farnesoid X receptor, or FXR, that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC, another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir, ABT-493, EDP-239, ABT-494 and EDP-494. ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Recent Trading Information
ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) closed its last trading session up +0.07 at 30.07 with 219,359 shares trading hands.